Executive Summary
Despite widespread awareness of EU MDR requirements and significant investment in regulatory infrastructure, a substantial proportion of technical documentation submissions continue to receive major non-conformities from Notified Bodies. These rejections are rarely about missing sections or incomplete templates—the documentation appears complete on its face. Rather, rejections stem from fundamental misunderstandings about what constitutes sufficiency in regulatory evidence, how reviewers assess clinical data adequacy, and where the threshold lies between technical compliance and demonstrable conformity.
This article examines why technically structured documentation fails scrutiny, identifies the most common patterns in Notified Body findings, and details the operational and strategic approaches that distinguish successful submissions from those trapped in revision cycles. For regulatory professionals navigating MDR certification, understanding these distinctions is not merely academic—it directly impacts timelines, commercial viability, and professional credibility.
Why This Topic Matters Now
The Medical Device Regulation fundamentally altered the evidentiary standard for market access in Europe. Unlike the Medical Device Directive, which permitted substantial reliance on standards and equivalence arguments, MDR demands demonstrable clinical evidence proportionate to device risk and novelty. This shift has created a structural problem: many regulatory teams approach documentation as a compliance exercise—assembling required sections, referencing applicable standards, and describing design outputs—without recognizing that Notified Bodies now function as critical evaluators of clinical and technical sufficiency, not administrative reviewers.
The consequences are material. First submissions that receive major non-conformities enter 3-6 month revision cycles, often requiring additional clinical data generation, manufacturing changes, or fundamental re-evaluation of intended use and classification. For manufacturers with product launch timelines, investor commitments, or expiring MDD certificates, these delays represent existential risk. For regulatory professionals, repeated rejections damage credibility internally and complicate career progression.
Moreover, Notified Body capacity constraints mean that resubmissions compete with new applications in already-constrained review queues. A rejected submission doesn’t simply return to the starting line—it may wait months for re-review, compounding delays. Understanding how to achieve acceptance on initial submission is therefore a competitive necessity, not merely best practice.
What the Regulations Say (With Clarity, Not Clauses)
MDR Annex II defines technical documentation requirements for most devices, while Annex III applies to specific higher-risk categories and clinical investigations. At their core, these annexes require manufacturers to demonstrate—not merely assert—that devices meet General Safety and Performance Requirements (GSPRs) through a combination of design documentation, verification and validation evidence, clinical evaluation, and risk management outputs.
The regulation distinguishes between objective evidence and statements of compliance. Objective evidence includes test reports, clinical data, post-market surveillance results, and risk analysis outputs. Statements of compliance—”Device meets ISO 14971,” “Design controls implemented per ISO 13485″—are insufficient without the underlying evidence demonstrating how compliance was achieved and why it’s adequate for the specific device.
Clinical evaluation, perhaps the most scrutinized element, must establish both safety and performance through a defined methodology: literature review, equivalence demonstration (if applicable), and clinical investigation data (when required). The threshold for “sufficient clinical evidence” is deliberately not prescriptive—it scales with device invasiveness, duration of contact, biological risk, and degree of innovation. This creates interpretive space that Notified Bodies fill through their assessment methodologies and reviewer judgment.
The essential principle: technical documentation must enable a third-party reviewer to independently conclude that GSPRs are met, risks are acceptable, and clinical evidence supports intended use claims. If the reviewer must make assumptions, infer conclusions, or accept assertions without supporting data, the documentation is deficient.
What Most Companies Get Wrong
Mistaking Structure for Substance
The most common failure pattern is structural compliance without evidential sufficiency. Documentation includes all required sections, follows Annex II/III structure, and appears comprehensive. Yet reviewers identify gaps because the content doesn’t actually demonstrate conformity—it describes processes, references standards, and summarizes conclusions without providing the underlying technical and clinical rationale.
For example, a risk management file may include a risk matrix showing all identified hazards, control measures, and residual risk acceptability decisions. Structurally complete. Yet if the file doesn’t explain why specific control measures were selected, how residual risk acceptability was determined (beyond “risk-benefit favorable”), and what clinical data informed the risk analysis, reviewers cannot verify that risk management was conducted rigorously. The documentation describes what was done, not why it was sufficient.
Treating Clinical Evaluation as a Literature Exercise
Many clinical evaluation reports (CERs) are constructed as annotated bibliographies: literature is identified, papers are summarized, and conclusions state that “available literature supports safety and performance.” This approach fundamentally misunderstands the CER’s purpose.
A robust CER doesn’t catalog literature—it critically appraises it. For each clinical claim in the intended use and instructions for use, the CER must demonstrate what evidence supports the claim, why that evidence is applicable to the subject device, and whether evidence quality and quantity are sufficient given the device’s risk profile. When equivalence is claimed, the CER must demonstrate not just substantial equivalence in technical and biological characteristics, but also in clinical performance.
Reviewers routinely reject CERs that:
- Rely on equivalence claims without demonstrating clinical similarity
- Include literature that describes the disease state or standard of care without addressing the specific device intervention
- Apply outdated or low-quality studies without acknowledging limitations
- Make performance claims not supported by the cited evidence
- Fail to address all GSPRs relevant to the device
The standard has risen. Literature reviews conducted under MDD are rarely sufficient under MDR without significant augmentation or clinical investigation data.
Underestimating the Post-Market Surveillance Section
Technical documentation must describe the post-market surveillance (PMS) system, not merely state that one exists. Reviewers assess whether the PMS plan is fit for purpose—whether it will actually generate data capable of confirming safety and performance throughout the device lifecycle.
Common deficiencies include:
- Generic PMS plans lacking device-specific data collection methods
- No clear linkage between residual risks and PMS monitoring parameters
- Vague incident monitoring without defined thresholds for trend analysis
- Absence of clear criteria triggering corrective action or field safety actions
- No articulation of how clinical follow-up data will be collected for implantable or long-term use devices
Notified Bodies increasingly scrutinize whether PMS plans will generate meaningful data or simply check regulatory boxes. If the plan wouldn’t detect safety signals or performance degradation, it’s deficient regardless of structural compliance.
Inconsistency Across Documentation Sections
Technical documentation is not a collection of independent documents—it’s an integrated evidence package. Reviewers assess consistency across risk management files, design verification reports, clinical evaluation, instructions for use, and labeling. When these elements contradict or misalign, it suggests either documentation inaccuracy or gaps in the quality management system.
For instance:
- Risk analysis identifies biological incompatibility as a hazard, but the clinical evaluation doesn’t address biocompatibility data
- Instructions for use claim a performance characteristic not validated in design verification testing
- Clinical evaluation concludes device is equivalent to a predicate, but design outputs show material differences
- Post-market surveillance plan doesn’t monitor parameters corresponding to identified residual risks
These inconsistencies are red flags. They suggest that documentation was prepared by siloed teams without cross-functional review, or that the technical file was assembled for regulatory submission rather than reflecting actual design and development processes.
Practical Implications for MedTech Professionals
For Regulatory Affairs Teams
Your role has expanded from documentation assembly to evidence synthesis. Success requires understanding not just what MDR requires, but what constitutes sufficient evidence in the reviewer’s framework. This means:
Developing clinical evaluation competency. If you cannot critically read clinical literature, assess study quality, and determine whether evidence supports specific claims, you cannot lead CER development. Clinical evaluation is no longer a task to delegate entirely to consultants.
Building cross-functional review protocols. Technical documentation quality depends on input from R&D, clinical affairs, quality, and post-market surveillance teams. Establishing structured review checkpoints throughout development—not just at submission—prevents downstream inconsistencies.
Implementing pre-submission gap analyses. Before submission, conduct internal reviews simulating Notified Body scrutiny. Identify sections where evidence quality is marginal, where equivalence claims lack robustness, or where clinical data gaps exist. Address these proactively rather than through major non-conformities.
For Quality and Compliance Leaders
Technical documentation deficiencies often reflect QMS gaps, not just submission errors. Recurring rejection patterns suggest systemic issues in how design controls, risk management, or clinical evaluation are executed.
Design history files must support technical documentation. If your DHF requires substantial reformatting or reinterpretation to populate technical documentation, the DHF is inadequate. Well-executed design controls should generate technical documentation as a natural output.
Risk management integration is not optional. Risk management files must demonstrably inform design decisions, verification testing, clinical evaluation scope, and PMS planning. If these connections aren’t explicit in documentation, reviewers will question whether risk management was genuinely integrated or merely performed to satisfy ISO 14971.
Post-market data must close the loop. Technical documentation describes PMS plans; quality systems must ensure those plans are executed and that data flows back into risk management and clinical evaluation updates. Notified Bodies increasingly audit PMS implementation, not just PMS plans.
For Clinical and R&D Teams
Clinical evaluation and design verification outputs are the evidentiary foundation of technical documentation. Weak or incomplete outputs cannot be remediated through clever regulatory writing.
Clinical investigation planning must consider MDR requirements. If your device will require clinical data, waiting until technical documentation preparation to determine data needs is too late. Clinical study design, endpoints, and follow-up duration must align with anticipated CER requirements and GSPR demonstration.
Design verification testing must be device-specific. Generic “meets ISO 10993” or “compliant with IEC 60601” statements are insufficient. Testing must demonstrate that your device, in your intended use, meets applicable requirements. Verification reports must explain test methodology selection, acceptance criteria rationale, and interpretation of results.
Equivalence claims require rigor. If claiming equivalence for clinical evaluation purposes, technical and biological equivalence must be demonstrated, not asserted. This requires comparative testing, materials analysis, and often clinical data comparison. Equivalence is not proven by general similarity—it requires specific, documented comparisons.
Impact on Careers, Compliance, and Inspections
Career Implications
Regulatory professionals are increasingly evaluated on submission success rates and time-to-approval metrics. Repeated major non-conformities raise questions about competency, diligence, and strategic judgment. Conversely, professionals who consistently achieve first-submission approval or minor-non-conformity-only outcomes build reputations as high-performers capable of navigating complex regulatory environments.
For those seeking advancement to senior regulatory or compliance leadership roles, demonstrated ability to lead successful MDR submissions is becoming table stakes. The market for regulatory talent values practical MDR implementation experience over theoretical knowledge.
Compliance and Inspection Risk
Technical documentation deficiencies often surface during regulatory authority inspections, not just Notified Body reviews. When competent authorities audit manufacturers, they assess whether technical documentation accurately reflects device design, manufacturing, and performance. Inconsistencies between technical documentation and actual device characteristics constitute misrepresentation—a serious compliance violation.
Moreover, if post-market data contradicts claims in technical documentation (e.g., adverse events suggest risks inadequately controlled, field performance doesn’t match validated performance), this triggers scrutiny of the entire submission. Was the technical documentation accurate at the time of submission? Were known issues omitted? These questions can escalate to warning letters, certificate suspension, or market withdrawal orders.
Commercial and Organizational Impact
Delayed certifications disrupt product launch timelines, affecting revenue projections and commercial partnerships. Distribution agreements often include certification date commitments; delays can trigger penalties or contract termination. For venture-backed companies, missed regulatory milestones can complicate funding rounds or reduce valuations.
Internally, regulatory delays strain cross-functional relationships. When submissions fail, blame often shifts to regulatory teams, even when root causes lie in inadequate design documentation, insufficient clinical data, or QMS gaps. Successful regulatory professionals manage these dynamics by setting realistic expectations, identifying risks early, and ensuring that executive leadership understands the evidentiary threshold required for approval.
What Smart Organizations Are Doing Differently
Leading medical device companies are implementing several strategic and operational changes to improve submission success rates:
Early Notified Body Engagement
Rather than waiting for formal submission, these organizations engage Notified Bodies during development for informal pre-submission consultations. While Notified Bodies cannot pre-approve documentation, they can clarify expectations for specific device categories, indicate whether proposed equivalence approaches are viable, and identify areas requiring additional data.
This early engagement allows manufacturers to course-correct before investing in complete documentation packages. It’s particularly valuable for novel devices, borderline classifications, or complex equivalence scenarios.
Integrated Documentation Development
Instead of treating technical documentation as a post-development compilation exercise, leading teams integrate documentation requirements into design and development workflows. Design reviews explicitly address technical documentation requirements; verification protocols are written with Annex II/III evidence requirements in mind; clinical evaluation planning begins at the concept stage.
This approach ensures that design history files and technical documentation align naturally, reducing inconsistencies and rework. It also distributes documentation effort across the development timeline rather than concentrating it at submission.
Clinical Evaluation as Continuous Process
Rather than treating clinical evaluation as a one-time submission deliverable, sophisticated manufacturers implement continuous clinical evaluation processes. Literature reviews are updated quarterly; new clinical data (from investigations or PMS) is systematically incorporated; GSPR demonstration is reassessed as new evidence emerges.
This approach ensures that CERs are current, robust, and defensible. It also facilitates rapid responses to Notified Body questions and streamlines periodic safety update reports and clinical evaluation report updates required under MDR Article 61.
Post-Market Surveillance Integration
Organizations achieving high submission success rates design PMS systems during development, not after market release. The PMS plan described in technical documentation reflects actual data collection capabilities, realistic monitoring parameters, and clearly defined review and action protocols.
These organizations recognize that PMS is not merely a regulatory requirement but a critical input to ongoing conformity assessment. They invest in systems that aggregate field data, analyze trends, and feed insights back into design, risk management, and clinical evaluation processes.
External Expertise with Internal Capability
While many organizations rely heavily on consultants for technical documentation, leading companies build internal expertise supplemented by strategic external support. Internal teams develop deep knowledge of Notified Body expectations, common rejection patterns, and device-specific evidence requirements. Consultants are engaged for specialized areas (complex clinical evaluation, novel technologies) rather than wholesale documentation outsourcing.
This balance ensures institutional knowledge accumulation, reduces dependency on external resources, and enables faster iteration when addressing Notified Body questions.
What’s Coming Next: Regulatory and Industry Outlook
Increasing Scrutiny of Software and AI/ML Devices
As software-based medical devices and AI/ML-enabled systems proliferate, Notified Bodies are developing more rigorous assessment frameworks for these technologies. Expect heightened scrutiny of:
- Algorithm validation methodologies and performance metrics
- Clinical evidence for AI-driven diagnostic or treatment recommendations
- Cybersecurity risk management and ongoing vulnerability monitoring
- Software maintenance and update protocols (particularly for adaptive algorithms)
Technical documentation for software devices must demonstrate not just that the algorithm performs as intended, but that performance is maintained across real-world variability, edge cases, and intended user populations.
Harmonization of EU and US Requirements
While MDR and FDA requirements differ structurally, convergence is occurring in evidentiary expectations. FDA’s increasing emphasis on clinical evidence for 510(k) submissions, real-world evidence utilization, and cybersecurity documentation parallels MDR approaches. Organizations preparing for both markets should leverage this convergence by developing integrated evidence packages addressing both regulatory frameworks.
Post-Market Data as Competitive Differentiator
As PMS and PMCF generate longitudinal device performance data, manufacturers with robust post-market systems will gain competitive advantages. Strong post-market data supports lifecycle management, demonstrates ongoing conformity during re-certification, and provides clinical evidence for product enhancements or line extensions.
Conversely, manufacturers with weak PMS systems will face increasing difficulty maintaining certifications and demonstrating continued conformity. Expect Notified Bodies and competent authorities to intensify PMS implementation audits.
Evolving Notified Body Expectations
Notified Body assessment methodologies continue to mature. Early MDR submissions faced inconsistent reviewer expectations as Notified Bodies adapted to new requirements. As experience accumulates, assessment approaches are stabilizing, but expectations are rising. Evidence that might have been acceptable in 2021-2022 may no longer suffice.
This evolution requires regulatory teams to stay current with Notified Body expectations through professional networks, industry forums, and ongoing dialogue with designated Notified Bodies.
Key Takeaways
Technical documentation success under EU MDR requires moving beyond structural compliance to demonstrating evidential sufficiency. Notified Bodies assess whether documentation enables independent verification that GSPRs are met, risks are controlled, and clinical evidence supports intended use.
The most common rejection patterns—inadequate clinical evaluation, generic risk management, weak PMS plans, and cross-document inconsistencies—are preventable through integrated development approaches and rigorous internal review.
For regulatory professionals, success requires both regulatory expertise and cross-functional leadership. The ability to synthesize clinical, technical, and quality evidence into cohesive documentation is increasingly what distinguishes high-performing regulatory functions.
Organizations that integrate technical documentation requirements into design and development processes, rather than treating documentation as a post-development exercise, achieve higher submission success rates and faster approval timelines.
As MDR implementation matures and Notified Body expectations evolve, the threshold for acceptable evidence continues to rise. Continuous professional development and staying current with regulatory trends are not optional—they are essential for career advancement and organizational success.
The gap between regulatory awareness and regulatory excellence is execution. Understanding what MDR requires is foundational; understanding what Notified Bodies accept is operational mastery. For medical device professionals committed to advancing their expertise beyond compliance checklists into strategic regulatory leadership, this distinction defines career trajectory.
AptSkill offers advanced, practitioner-focused training in regulatory affairs, clinical evaluation, risk management, and quality systems—designed for professionals who need operational excellence in navigating complex regulatory environments. Because advancing MedTech requires mastering not just what regulations say, but what successful submission requires.